MEN1 and metastatic malignant neoplasm: Of those with no changes to their medical care, 5 (20.8%) werealready followed appropriately due to a clinical diagnosis (APC, n= 3; MEN1, n = 1; STK11, n = 1),2 (8.3%) had metastatic cancer, and 1 (4.2%) already had increased surveillance dueto a prior diagnosis (MUTYH heterozygote with colon cancer).Additionally, single-site GT was recomnended for all first-degree relatives ofPV/LPV carriers identified via retesting.